Endocrine Pathology

, Volume 6, Issue 4, pp 301–310 | Cite as

Incidence, pathology, and recurrence of pituitary adenomas: Study of 647 unselected surgical cases

  • Takahiko Terada
  • Kalman Kovacs
  • Lucia Stefaneanu
  • Eva Horvath
Clinical Research


The incidence of various types of unselected pituitary adenomas based on correlation of pathologic and clinical data was assessed. We investigated 647 cases of unselected pituitary adenomas, which were surgically removed between 1980 and 1993. All cases were examined by immunohistochemistry and electron microscopy. The mean age of patients was 44.0 years with 40.0 years for women (55.2%) and 49.1 years for men (44.8%). Age distribution indicated a remarkable sex difference: 52.4% of women and 26.8% of men were between 21 and 40 years at the time of surgery. Based on immunohistochemistry and electron microscopy, prolactin (PRL) cell adenomas represented 26.3% of tumors, growth hormone (GH) cell adenomas 12.5%, adrenocorticotrophic hormone (ACTH) cell adenomas 12.4%, oncocytomas 12.4%, and gonadotroph cell adenomas 9.4%. Seventy-three percent of the prolactinomas occurred in women and 73.8% of the oncocytomas were found in men. The incidence of pediatrics pituitary adenomas was 4.6%. All 647 cases were followed up; the mean follow-up period was 96.6 months. In 40 patients (6.2%), the adenoma recurred. Recurrence was common in functioning ACTH cell adenomas (8 cases: 9.5%) followed by silent adenomas (7 cases: 25.9%). Recurrence was noted after 2–96 months (average 28.7 months) following surgery. The shortest remission period was found in a patient with oncocytoma followed by a patient with prolactinoma.

Key Words

Pituitary adenomas incidence histologic characteristics recurrence remission periods 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Kovacs K, Horvath E. Pituitary adenomas. In: Hartomann WH, ed. Atlas of tumor pathology, 2nd ser. Fascicle 21. Washington, DC: Armed Forces Institute of Pathology, 1986; 57–69.Google Scholar
  2. 2.
    Richmond IL, Wilson CB. Pituitary adenomas in childhood and adolescence. J Neurosurg 49:163–168, 1978.PubMedCrossRefGoogle Scholar
  3. 3.
    Burrow GN, Wortzman G, Rewcastle NB, Holgate RC, Kovacs K. Microadenomas of the pituitary and abnormal sellar tomograms in an unselected autopsy series. N Engl J Med 304:156–158, 1981.PubMedCrossRefGoogle Scholar
  4. 4.
    Parent AD, Brown B, Smith EE. Incidental pituitary adenomas: a retrospective study. Surgery 92:880–883, 1982.PubMedGoogle Scholar
  5. 5.
    McComb DJ, Ryan N, Horvath E, Kovacs K. Subclinical adenomas of the human pituitary. New light on old problems. Arch Pathol Lab Med 107:488–491, 1983.PubMedGoogle Scholar
  6. 6.
    Mukai K. Pituitary adenomas immunohistochemical study of 150 tumors with clinicopathologic correlation. Cancer 52:648–653, 1983.PubMedCrossRefGoogle Scholar
  7. 7.
    Hsu SM, Raine L, Fanger H. A comparative study of the peroxidase-antiperoxidase method and an avidin-biotin complex method for studying polypeptide hormones with radioimmunoassay antibodies. Am J Clin Pathol, 75:734–738, 1981.PubMedGoogle Scholar
  8. 8.
    Hsu SM, Raine L, Fanger H. The use of antiavidin antibody and avidin-biotin-peroxidase complex immunoperoxidase techniques. Am J Clin Pathol 75:816–821, 1981.PubMedGoogle Scholar
  9. 9.
    Horvath E, Kovacs K. Pituitary gland. Pathol Res Pract 183:129–142, 1988.PubMedGoogle Scholar
  10. 10.
    Horvath E, Kovacs K. The adenohypophysis. In: Kovacs K, Asa SL, eds. Functional endocrine pathology. Boston, Blackwell, 1991; 245–281.Google Scholar
  11. 11.
    Horvath E, Kovacs K, Smyth HS, Killinger DW, Scheithauer BW, Randall R, Laws ER, Singer W. A novel type of pituitary adenoma: morphological features and clinical correlations. J Clin Endocrinol Metab 66:1111–1118, 1988.PubMedGoogle Scholar
  12. 12.
    Faglia G. Epidemiology and pathogenesis of pituitary adenomas. Acta Endocrinol 129 (Suppl. 1):1–5, 1993.PubMedGoogle Scholar
  13. 13.
    Mindermann T, Wilson CB. Age-related occurrence of pituitary adenomas. Clin Endocrinol 41:359–364, 1994.Google Scholar
  14. 14.
    Takakura K. Age distribution of pituitary adenomas. In: Takakura K, ed. Brain tumor registry in Japan, vol. 8 Tokyo: The Committee of Brain Tumor Registry of Japan, 1993; 15–33.Google Scholar
  15. 15.
    Robinson N, Beral V, Ashley JSA. Incidence of pituitary adenoma in women. Lancet 2:630, 1979.CrossRefGoogle Scholar
  16. 16.
    Gold EB. Epidemiology of pituitary adenomas. Epidemiol Rev 3:163–183, 1981.PubMedGoogle Scholar
  17. 17.
    Kovacs K, Horvath E. Adenomas with prolactin production. In: Atlas of tumor pathology, 2nd ser. Fascicle 21. Washington, DC: Armed Forces Institute of Pathology, 1986; 96–115.Google Scholar
  18. 18.
    Horvath E, Kovacs K. Pathology of prolactin cell adenomas of the human pituitary. Semin Diagn Pathol 3:4–17, 1986.PubMedGoogle Scholar
  19. 19.
    Styne DM, Grumbach MM, Kaplan SL, Wilson CB, Conte FA. Treatment of Cushing disease in childhood and adolescence by transsphenoidal microadenomectomy. N Engl J Med 310:889–893, 1984.PubMedCrossRefGoogle Scholar
  20. 20.
    Haddad SH, VanGilder JC, Menzes AH. Pediatric pituitary tumors. Neurosurgery 29:509–514, 1991.PubMedCrossRefGoogle Scholar
  21. 21.
    Partington MD, Davis DH, Laws ER, Scheithauer BW. Pituitary adenomas in childhood and adolescence. Results of transsphenoidal surgery. J Neurosurgery 69:209–216, 1994.Google Scholar
  22. 22.
    Landolt AM, Kleihues P, Heitz PU. Amyloid deposits in pituitary adenomas. Arch Pathol Lab Med 111:453–458, 1987.PubMedGoogle Scholar
  23. 23.
    Landolt AM, Rothenbühler V. Pituitary adenoma calcification. Arch Pathol Lab Med 101:22–27, 1977.PubMedGoogle Scholar
  24. 24.
    Ilse G, Ryan N, Kovacs K. Calcium deposition in human pituitary adenomas studied by histology, electron microscopy, electron diffraction and X-ray spectrometry. Exp Pathol 18:377–386, 1980.Google Scholar
  25. 25.
    Benedict R, Gerard M, Robert F, Hardy Y. Calcifications in pituitary adenomas. Surg Neurol 15:249–255, 1981.CrossRefGoogle Scholar
  26. 26.
    Grossman A, Ross R, Was JAH, Besser GM. Depot-bromocriptine treatment for prolactinomas and acromegaly. Clin Endocrinol 24:231–238, 1986.Google Scholar
  27. 27.
    Montini M, Pagani G, Gianol D, Pagani MD, Sahnoraighi M, Ferrari L, Lancranjan I. Long-lasting suppression of prolactin secretion and rapid shrinkage of prolactinomas after a long-acting injectable form of bromocriptine. J Clin Endocrinol Metab 63:266–268, 1986.PubMedCrossRefGoogle Scholar
  28. 28.
    Kovacs K, Stefaneanu L, Horvath E, Lloyd RV, Lancranjan I, Fahlbush R. Effect of dopamine agonist medication on prolactin producing pituitary adenomas. Virchows Arch A Pathol Anat 418:439–446, 1991.CrossRefGoogle Scholar
  29. 29.
    Kovacs K, Horvath E. Gonadotroph cell adenoma. In: Hartomann WH, ed. Atlas of tumor pathology, 2nd ser. Fascicle 21. Washington, DC: Armed Forces Institute of Pathology, 1986; 170–178.Google Scholar
  30. 30.
    Mindermann T, Kovacs K, Wilson CB. Changes in the immunophenotype of recurrent pituitary adenomas. Neurosurgery 35:39–44, 1994.PubMedCrossRefGoogle Scholar
  31. 31.
    Nakane T, Kuwahara A, Watanabe M, Takahashi T, Kato T, Ichihara K, Kageyama N. Long-term results of transsphenoidal adenomectomy in patients with Cushing's disease. Neurosurgery 21:218–222, 1987.PubMedCrossRefGoogle Scholar

Copyright information

© Humana Press Inc 1995

Authors and Affiliations

  • Takahiko Terada
    • 1
  • Kalman Kovacs
    • 1
  • Lucia Stefaneanu
    • 1
  • Eva Horvath
    • 1
  1. 1.Department of Pathology, St. Michael’s HospitalUniversity of TorontoCanada

Personalised recommendations